Multidimensional family therapy (MDFT) treatment of adolescents with substance use disorders, focusing on risk and protective factors in major youth life domains

Conditions

Cannabis abuse and cannabis dependence Mental and Behavioural Disorders Mental and behavioural disorders due to use of cannabinoids

Thimo M. van der Pol, Moran D. Cohn, Lieke van Domburgh, Henk Rigter, Robert Vermeiren

Journal of Experimental Criminology2020-05-022 citations

10.1007/s11292-020-09431-0

Multidimensional family therapy in adolescents with a cannabis use disorder: long-term effects on delinquency in a randomized controlled trial

Thimo M. van der Pol, Vincent M. Hendriks, Henk Rigter, Moran D. Cohn, Theo Doreleijers et al. (7 authors)

Child and Adolescent Psychiatry and Mental Health2018-08-1722 citations

10.1186/s13034-018-0248-x

Multidimensional family therapy decreases the rate of externalising behavioural disorder symptoms in cannabis abusing adolescents: outcomes of the INCANT trial.

Schaub MP, Henderson CE, Pelc I, Tossmann P, Phan O, Hendriks V, Rowe C, Rigter H.

2014-01-3120 citations

10.1186/1471-244x-14-26

European youth care sites serve different populations of adolescents with cannabis use disorder. Baseline and referral data from the INCANT trial.

Phan O, Henderson CE, Angelidis T, Weil P, van Toorn M, Rigter R, Soria C, Rigter H.

2011-07-1213 citations

10.1186/1471-244x-11-110

INCANT: a transnational randomized trial of multidimensional family therapy versus treatment as usual for adolescents with cannabis use disorder.

Rigter H, Pelc I, Tossmann P, Phan O, Grichting E, Hendriks V, Rowe C.

2010-04-0920 citations

10.1186/1471-244x-10-28

Interventions

MDFT: 4 - 6 months

sessions 2 - 3 times a week. Office-based and home-based sessions with: 1. The adolescent alone 2. The parent(s) alone 3. The family = adolescent + parent(s), and 4. Representatives of other social sy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age of the adolescent 13 through 18 years, either sex 2. Diagnosis of cannabis use disorder 3. At least 1 parent willing to take part in the treatment programme 4. Informed consent by both adolescent and parent(s)

Exclusion criteria

Exclusion criteria: 1. Disorder requiring hospitalisation or other residential treatment 2. Intelligence Quotient (IQ) of adolescent below 70

Design outcomes

Primary

Measure	Time frame
1. MDFT reduces cannabis consumption more strongly than TAU in the 90-day periods preceding follow-up assessments points (a lower number of consumption days: TLFB = TimeLine Follow Back), the difference growing bigger over time 2. Number of urine tests indicative of cannabis use is lower in MDFT than in TAU at follow-up assessments points 3. In MDFT, youth show fewer (symptoms of) diagnoses of cannabis use disorders (as measured with the Adolescent Diagnostic Interview-Light [ADI-Light]) than in TAU at 12 months follow-up (the validated ADI-Light measures symptoms of substance use disorders). Assessment points: baseline, 12 months follow up.	—

Measure

Time frame

1. MDFT reduces cannabis consumption more strongly than TAU in the 90-day periods preceding follow-up assessments points (a lower number of consumption days: TLFB = TimeLine Follow Back), the difference growing bigger over time 2. Number of urine tests indicative of cannabis use is lower in MDFT than in TAU at follow-up assessments points 3. In MDFT, youth show fewer (symptoms of) diagnoses of cannabis use disorders (as measured with the Adolescent Diagnostic Interview-Light [ADI-Light]) than in TAU at 12 months follow-up (the validated ADI-Light measures symptoms of substance use disorders). Assessment points: baseline, 12 months follow up.

—

Secondary

Measure	Time frame
1. MDFT reduces alcohol consumption to a greater extent than TAU, on the same measures and the same assessment points as outlined for cannabis 2. MDFT is superior to TAU in diminishing delinquent behaviour (less recidivism), as measured with the validated Adolescent and Parent Interviews, the Self-Reported Delinquency survey (SRD; lower score), lower scores on the delinquency sub-scales of Youth-Self Report (YSR) and its parent version, the Child Behaviour Checklist (CBCL). Also police and justice registration databases. Assessment points: baseline, 6 months and 12 months follow up. 3. MDFT improves family functioning more than TAU (validated Adolescent and Parent Interviews using the Family Environment Scale [FES]). Interviews: baseline, 6 months and 12 months follow-up. FES: idem, but also 9-months follow up. 4. MDFT improves the youth's performance at school or work more than TAU (validated Adolescent and Parent Interviews, school reports, truancy logs). Assessment points: baseline, 6 months and 12 months follow up.	—

Measure

Time frame

1. MDFT reduces alcohol consumption to a greater extent than TAU, on the same measures and the same assessment points as outlined for cannabis 2. MDFT is superior to TAU in diminishing delinquent behaviour (less recidivism), as measured with the validated Adolescent and Parent Interviews, the Self-Reported Delinquency survey (SRD; lower score), lower scores on the delinquency sub-scales of Youth-Self Report (YSR) and its parent version, the Child Behaviour Checklist (CBCL). Also police and justice registration databases. Assessment points: baseline, 6 months and 12 months follow up. 3. MDFT improves family functioning more than TAU (validated Adolescent and Parent Interviews using the Family Environment Scale [FES]). Interviews: baseline, 6 months and 12 months follow-up. FES: idem, but also 9-months follow up. 4. MDFT improves the youth's performance at school or work more than TAU (validated Adolescent and Parent Interviews, school reports, truancy logs). Assessment points: baseline, 6 months and 12 months follow up.

—

Countries

Belgium, France, Germany, Netherlands, Switzerland

Outcome results

None listed